Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Re: Hanlon's razor
That's a good one! I'll have to remember that.
These guys have been in the locker room so long, that maybe it's time they actually see the playing field!
Re: the people running the show hold all the stock so it wouldn't make sense for them to do things that don't support PPS. I think things are looking very positive now!
I agree. I also like that Medite shows nice revenue which we never had, and hopefully a good network to spread the word around.
How many lives does this little company have? The doors could have and should have been closed too many time to count over what seems like at least a decade. With minimal profit or mostly losses for so many years, lawsuits that were pending and settled, talk of an SEC scandal, and employees you can count on just a few fingers, I am shocked Cytocore is trying to look like that little train who could. There was not one post on the Investors Hub Cytocore board for about a year until a few days ago. Throughout all this turmoil McCullough would still file the reports necessary to keep on existing. One can only think someone knew it was important to keep the patents Cytocore has up to date and keep all the I's dotted and T's crossed until the right fit came along for Cytocore's suite of products. Could this fit possibly be Medite? I really hope this is the real deal this time and not just another pump and dump. This stock fit the pump and dump mold too many times in the past it was more than just a bit comical. I hope we get some good leadership this time around that will walk the talk instead of talking the talk. I still have most of my shares from several private offerings and then what I purchased on the open market when I actually bought into most of what I was told, and that Cytocore could be a very lucrative situation. Let's hope we move forward this year or next and not go back to being stagnant for yet another 5 or 10 years. One thing for sure is that I am not emotionally invested anymore and if something good happens that is more than just talking points, it will just be a bonus on top of what really has been a terrible nightmare.
Wow, still under $.04 pre-split. I wonder if McCullough's hedge fund is waiting to load up at his preferred $.17-$27 range. I also wonder, since rules don't seem to apply, when this will be run up so his hedgefund can dump for a 5-10 bagger. With Madoff types out there, I don't think the SEC cares about McCullough's penny stock shares or what he does with them.
Interesting
152 posts in 3 weeks (11/6-11/26) when CYOE was hitting a bottom, and 14 posts last 6 weeks (11/26-01/07) when CYOE has risen from the dead 500%. I do understand this stock is still around $.07 pre-split, and I have been in the stock for years, but it seems there might have been a few big negative nellie posters who went on to other boards.
As I understood the marketmakers,
If there are no buyers and someone wants to sell, they set the price and buy the stock themselves. Either way it had to be arranged with a MM as there was not 330K sitting at level II at that price at the time.
The price is dropping daily on minimal shares traded per the float. I know there is not any mass selling. It's all small volume, but the MM's are dropping it like a rock. There still has not been mass selling, nor has there been mass buying. No interest either way.
20-Day Close M.A. 0.5060
50-Day Close M.A. 0.6050
65-Day Volume M.A. 38,903
We closed ar $.25 today
It does not make sense with the low volume of trading. I realize the company is marketed very poorly, but someone wants this share price low for a reason. If not the company is a certified POS.
Has anyone found any info if the 330K+ share trade was a buy or a sell?
I thought Friday's lone $70 trade might have been McCullough Dollar Cost Averaging Down his position. As the CEO he has not generated any buying interest for quite some time now from the institutional investors as well as the retail investor!!Nice job Robert...
The MM's brought this as low as they could as long as they knew or could see on Level II stock was there for the taking. Whether they were stop losses or it was just utilizing the intimidation factor, dropping the Bid so low to entice small investors to get out with at least a few bucks left of their investment. Some people could not afford to hold any longer with the thought of it actually going down and out and possibly under. Tax selling is coming up and holidays, loss of work, and just needing cash. Once they hit the new low, and knowing the trial results were in range, it has down a 360. Notice action has now been at the ask and has done a double in the last 10 days or so. McCullough’s last few piddly buys were bought down approaching the new yearly low. Since hitting $.36 just this month, it has been approaching a double on the upside. They cleaned out any sellers and it looks like it should be now be close to a ready for a steady run. Good news that is expected, and with some well placed PR, could get the SP to do a few more quick doubles to the upside. This low float, along with 38% insider ownership, some motivated market makers with a new mindset could power shift the stock to tolerable levels again. Such a low float since the reverse split would make this quite easy to do. If it does, I would hope it would be sustainable and the MM's would have bottom fished for the last time at those new recent yearly lows.
Time will tell, and hopefully this year.
Looks like a New Low, before any New Highs
No volume, no buyers, no interest!!
Is there a bottom?
CytoCore Reports 2007 Financial Results and Recent Progress
Company Poised for Rapid Market and Manufacturing Expansion and Ongoing Trials in 2008
CHICAGO -- April 3, 2008 – CytoCore Inc. (OTCBB:CYOE), the developer of a suite of cost-effective cervical cell collection devices for the early detection of cancer and sexually transmitted diseases, today reported 2007 year-end financial results. The company also provided an update on the progress it has made in expanding its presence within the global medical device market, including initial international distribution and new FDA approval.
“We regard 2007 as a watershed year and real turning point for the Company,” said CEO Robert McCullough, Jr. “Our ongoing progress in marketing and sales along with technology developments have positioned us for a productive 2008. The reduction of liabilities to approximately $1.5 million and the addition of $6 million equity capital both which occurred during the first quarter of 2008 along with the other financial restructuring during 2006 and 2007 including the reverse stock split provides us with the capital structure to launch the growth phase of CytoCore.
The Company reported revenue of $83,000 in 2007. This included the first sales of the SoftPAP product which commenced European sales in the fourth quarter of 2007. The Company reported a net loss of $8.24 million in 2007 or $.24 per share versus a loss of $7.2 million or $.30 per share in 2006.
Major advances in 2007 for CytoCore Solutions™ include: CE Marking and the receiving of FDA clearance for its SoftPAP® Collector, progress with key clinical trials, and the market launch of the SoftPAP® Collector in Europe. The Endoscan phase I trial, which utilized tissue slices from biopsy specimens in order to gather data to support the development of a cytological (cell-based) screening test for endometrial cancer, was concluded in July 2007. Development of a cytological endometrial cancer screening assay for use in conjunction with the AIPS platform is continuing. Meanwhile, the Collector Colposcopy trial is expected to reach its 650-patient objective by May of 2008, with results available shortly thereafter.
In the area of manufacturing engineering, CytoCore has partnered with the Engineered Plastics and Rubber Group of ATP to successfully initiate semi-automated commercial production of the SoftPAP® Collector in China. A fully automated manufacturing line is nearing completion in China and additional SoftPAP® manufacturing capacity is being brought on-line in Elkhorn, Wisconsin and Tempe, Arizona. The SoftPap Collector is now being shipped internationally to various distribution outlets. “We are now in the ramp-up stage, and are ready to produce and ship in quantities responsive to expanding worldwide demand – in line with CytoCore’s overall business plan and marketing goals,” said McCullough. “Moving the SoftPAP® Collector into manufacturing and distribution was a principal focus and achievement for us this past year.”
As a result of that focus, CytoCore’s SoftPAP® Collector received CE Mark approval for distribution into Europe in the third quarter of 2007, and the Company signed new distribution agreements for Italy, Spain and Portugal. The decision to hire Dr. Augusto Ocana as president of international distribution further enhanced this effort, which culminated at year-end with an initial shipment of SoftPAP® Collectors to markets in Italy. Subsequently, SoftPap Collectors have been shipped to Spain and Portugal, and a new distribution agreement has been signed for Switzerland with several other countries close at hand.
Other tactical executive appointments included McCullough’s expanded executive role as CEO, the addition of Dick Domanik as COO and President, and the election of several dynamic new board members.
The Company also strengthened its AIPS (Automated Image-Guided Proteomic System) development project with the addition of Dr. Michael Jolley, whose strength in Assay development was demonstrated by his success in developing Assays for Abbot Lab’s TDX system (the first ever automated drug monitoring system). His understanding of the needs and potential of the AIPS project positions CytoCore for rapid progress that is expected to produce a beta version of the AIPS, with two key assays, scheduled for testing in the fourth quarter of 2008.
“Our achievements in 2007 are consistent with the goals we articulated at year-end in 2006,” said McCullough. “As a result of our execution, we have established CytoCore as an institutional quality investment and were able to raise $10 million in new equity financing -- despite a challenging market. We have positioned ourselves for continued growth with medical screening and other devices that respond directly to well-documented global health crises such as the epidemic of HPV infection among young women in the United States and abroad.”
About CytoCore Inc.
CytoCore develops cost-effective, highly accurate screening systems for early detection of gynecological cancers and sexually transmitted diseases. Designed for easy deployment at a laboratory or at the point-of-care, the CytoCore suite of sample collection technologies assists in the detection of cervical, endometrial, and other cancers, as well as the human Papilloma virus. The CytoCore Solutions™ System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com.
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the CytoCore Solutions™ System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
Contact:
CytoCore, Inc.
Robert McCullough, Jr., 312-222-9550
or
EVC Group
Douglas Sherk/Matthew Selinger, 415-896-6820
mselinger@evcgroup.com
CytoCore Signs Agreement For Distribution in Switzerland
CHICAGO March 26, 2008-CytoCore, Inc. (OTCBB:CYOE), a leading developer of cost-effective cancer screening systems to assist in the early detection of cervical, endometrial, and other cancers, announced today that it has entered into a four year agreement with HT Hospital Technologies GmbH, a subsidiary of M.O.S.S. S.r.l. for distribution of the SoftPAP® Cervical Cell Collector into Switzerland. M.O.S.S specializes in the distribution and maintenance of medical and surgical devices. HT Hospital Technologies’ agreement calls for minimum sales of 150,000 units the first year, 200,000 units the second, and 250,000 units the third year.
CytoCore CEO Robert McCullough Jr. stated “We are very pleased to expand our distribution into another European market. Franco Pappa, President of MOSS continues to demonstrate his support and enthusiasm for the SoftPAP® Collector by expanding his distribution territory from Italy to include Switzerland as well. Mr. Paolo Burg is leading HT Hospital Technologies and is going to be responsible for the SoftPAP® distribution in Switzerland. We expect to receive an initial order to ship first SoftPAP® products to Switzerland by mid-April.”
About M.O.S.S.
M.O.S.S. S.r.l. was founded in 2000 as part of a larger group of medical distribution companies under the direction of Franco Papa. M.O.S.S. is a part of TIMANT, a European wide Service Network for medical equipment. For more information on M.O.S.S. S.r.l., visit their web site: www.MOSS-info.it
The SoftPAP® Cervical Cell Collector offers a quicker, more comprehensive way of collecting a specimen for Pap testing while minimizing the patient discomfort traditionally associated with the collection of this type of sample. SoftPAP® uses a patented single-use medical grade silicone rubber balloon to collect the sample. When the tip of this balloon is inserted into the endocervical canal and the balloon is inflated, it expands to contact the entire region from which a sample is to be obtained. Collecting the entire sample in a single step without the need to rotate or reposition the collector provides the physician with ease of use while reducing the possibility of sample collection errors. Unlike the rigid, hard edged cervical cell collection devices of the past, SoftPAP®’s soft, compliant balloon and controlled inflation promotes patient comfort by eliminating the need to scrape or abrade the cervix in order to obtain an adequate sample. The goal is to have a more comfortable procedure for the patient and ease of use for the physician. Additionally, the SoftPAP® was designed to collect cells with a “one touch” process, to reduce inadequate specimen collection. The theory is that the better specimen, the better chance of early detection of cervical dysplasia and related HPV.
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The CytoCore Solutions(tm) System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the CytoCore Solutions™ System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
Contact: Robert McCullough, Jr. Douglas Sherk/Matthew Selinger
CytoCore, Inc. EVC Group
(312) 222-9550 (415) 896-6820
mselinger@evcgroup.com
CytoCore Signs First U.S. Distributor for SoftPAP(TM) Cell Collectors
( BW)(IL-CYTOCORE)(CYOE) CytoCore Signs First U.S. Distributor for
SoftPAP(TM) Cell Collectors
Company Ships First U.S. Order
Business Editors/Medical Editors
CHICAGO--(BUSINESS WIRE)--March 17, 2008--CytoCore Inc.
(OTCBB:CYOE), a leading developer of cost-effective cancer screening systems to assist in the early detection of cervical, endometrial, and other cancers, announced today its first U.S. distribution agreement and first U.S. order for its SoftPAP (TM) cell collector, the revolutionary sample collection device, with CoMedical, Inc., headquartered in Seattle, Washington (www.comedical.com).
Privately held CoMedical, Inc. was founded in 1980 and serves healthcare professionals in Washington, Oregon, Idaho, Montana, Wyoming and Alaska. The Company focuses on representing small innovative healthcare product manufacturers to introduce their products to targeted healthcare professionals.
The SoftPAP Cervical Cell Collector offers a quicker, more accurate specimen collection for the Pap test with minimal possibility of user error. SoftPAP is designed to collect a full 360 degree specimen from both the cervical canal and the outer surface of the cervix, simultaneously resulting in a more complete and comprehensive specimen for testing. It is designed to consistently sample the entire cervix in a single-step using an inflatable balloon collector. The patented single-use silicon balloon is a mirror image of the surface of the ecto- and endo-cervix. During collection, the balloon is slightly inflated by pressing a button on the collector handle. The volume of air is fixed and controlled so no over or under inflation can occur. The balloon is designed so that regardless of the shape of the cervix, when the balloon inflates, the balloon's surface comes into contact with all walls of the cervix that need sampling in a single step. Cells are collected from 360 degrees around the ecto-cervix, and from within the endo-cervix by touch. No rotation of the Collector is necessary. Results include greater patient comfort and ease of use for the physician, and greater cellularity thereby reducing the inadequate specimens for analysis. When compared to traditional cell collection techniques, clinical studies have shown that while collecting a better quality specimen, SoftPAP reduces patient adverse events, primarily bleeding and spotting, by 95%. By virtually eliminating "adverse events," the SoftPAP should help overcome any patient reluctance to having the Pap test, which, in turn, should provide a method to increase early detection of HPV and potentially related cervical dysplasia.
"The SoftPAP cervical cell collector is a major advancement for the Pap test," said Robert McCullough, Jr., President & CEO of CytoCore. "The Collector offers much greater patient comfort as well as improved physician confidence in the test sample by acquiring a more complete and comprehensive cervical specimen for more consistently reliable Pap test results. As with the launch of any new medical device, it is critical to work with the right partners who have proven abilities to develop market opportunities. CoMedical is such a partner. Their focus on the Pacific Northwest and their emphasis on working with innovative manufacturers such as CytoCore are both characteristics that enhance our team's potential for success with the Collector's introduction in this country. We expect this agreement to be the first of a number of regional distribution agreements we will sign in the near future as CytoCore expands its production and marketing plans in the U.S.," Mr. McCullough added.
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The CytoCore Solutions(tm) System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at:
www.CytoCoreInc.com.
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the CytoCore
Solutions(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
--30--
CONTACT: CytoCore, Inc.
Robert McCullough, Jr., 312-222-9550
or
EVC Group
Douglas Sherk/Matthew Selinger, 415-896-6820
mselinger@evcgroup.com